Skip to content

Peptides and Cancer Risk: The Warning, the Theory, the Unknowns

The FDA thyroid C-cell boxed warning on GLP-1 labels, the theoretical concern with growth-factor and angiogenic peptides, and what long-term data does not exist.

Sebastian Hunter, Founder and EditorWritten bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

The short version

Three separate things get lumped under "peptides and cancer". One is a real, FDA-mandated boxed warning on approved GLP-1 drugs, based on a rodent finding of unknown human relevance. The second is a theoretical concern: growth-factor and angiogenic peptides work through pathways that could in principle also support tumour growth, though nobody has tested this as a clinical outcome. The third is a gap: no large, long-term cancer-incidence study exists for most peptides sold today, approved or not.

  • Every approved GLP-1 drug carries a boxed warning for thyroid C-cell tumours seen in rodents. Human relevance is stated as unknown, not as ruled out.
  • Angiogenic and growth-factor peptides (e.g. BPC-157, GH secretagogues) act on pathways tumours can also use. That is a mechanistic inference, not an observed cancer risk.
  • No long-term human cancer-incidence data exists for most research peptides, so no reported signal is not a clean bill of health.
  • Approved products name contraindications for a personal or family history of MTC or MEN 2. Talk to a prescriber rather than self-manage the risk.

“Peptides and cancer” is three questions, not one:

  • a real, FDA-mandated boxed warning on approved GLP-1 drugs
  • a theoretical concern with peptides that promote blood-vessel growth or raise growth-factor levels
  • a gap in the evidence: long-term cancer-incidence data does not exist for most peptides on the market

This page keeps the three separate and says what is known, what is inferred, and what nobody has measured.

The thyroid C-cell boxed warning on GLP-1 labels

Every FDA-approved GLP-1 receptor agonist carries a boxed warning, the agency’s strongest label warning class, for thyroid C-cell tumours. The finding comes from rodent studies, and each label is explicit about what that does and does not establish.

The wording is deliberate. It states a rodent finding as fact, states human relevance as unknown (neither confirmed nor ruled out), and turns the uncertainty into a specific contraindication rather than a vague caution. Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and liraglutide (Victoza, Saxenda) all carry this warning. See the full labels: semaglutide, tirzepatide, liraglutide.

US legal status - FDA-approved · prescription only

Semaglutide, tirzepatide and liraglutide are FDA-approved, prescription-only medicines. The boxed warning is printed on their approved labels - it is not a research-chemical rumour, and it is not evidence the drugs are unsafe to prescribe; it is a disclosed, monitored risk.

One nuance: orforglipron, an oral GLP-1 drug, carries the same boxed warning even though its own label states it did not produce tumours in the rodent studies run on it. It does not activate the rodent GLP-1 receptor the way it activates the human one. So the warning attaches to the drug class and the human receptor, not only to what happened in a specific animal study. See orforglipron for the full distinction.

The theoretical concern: growth-factor and angiogenic signalling

This is a different kind of claim. Some peptides activate pathways that promote new blood-vessel growth (angiogenesis) or raise circulating growth factors. Tumours, once past a small size, depend on those same pathways to keep growing. That overlap is real biology. Whether it means these peptides raise cancer risk in a person has not been tested. It is an inference from mechanism, not an observed clinical outcome.

Angiogenic peptides: BPC-157 as the clearest example

BPC-157 is studied for its pro-angiogenic activity. Laboratory work has linked it to VEGFR2 activation and up-regulation, part of the signalling pathway that drives new blood-vessel formation. Hsieh 2017 - Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333., in the references below Reviews of the wider BPC-157 literature describe extensive preclinical work with consistently positive healing results. They state that efficacy has not been confirmed in humans Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159., in the references below and that it has not been approved for medical use due to insufficient comprehensive clinical studies. Józwiak 2025 - Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2)., in the references below

None of that literature tested tumour growth or cancer incidence as an outcome, in humans or in animal cancer models. The concern is a reasonable question raised by the mechanism, not a result anyone has published in either direction. The full BPC-157 page states this the same way.

Growth-factor peptides: the IGF-1 question

Growth hormone secretagogues (sermorelin, tesamorelin, ipamorelin, hexarelin, the GHRPs, MK-677) work by raising growth hormone, which in turn raises IGF-1. In hypogonadal men, GH secretagogue treatment measurably raises serum IGF-1 levels. Sigalos 2017 - Sigalos JT, Pastuszak AW, Allison A et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017;11(6):1752-1757., in the references below IGF-1 is a genuine growth factor with a documented role in cell proliferation. That is textbook physiology, not a peptide-specific claim.

A placebo-controlled safety trial of tesamorelin in people with type 2 diabetes reported on its metabolic and safety profile over the study period. That is the kind of monitoring that exists for an approved indication and mostly does not exist for a research-peptide GH secretagogue bought online. Clemmons 2017 - Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538., in the references below

Raising IGF-1 is documented. Whether that translates into a measurably higher cancer risk from any of these peptides has not been established in controlled human data. It remains an open, biologically reasonable question.

Peptides used to treat cancer, and general safety

Is there a peptide that kills cancer?

Not in the sense of a peptide destroying cancer cells directly. Several FDA-approved peptide drugs are used to treat cancer, but they work by cutting off a hormone signal a tumour depends on, not by killing cells outright.

Leuprolide acetate is a synthetic nonapeptide analogue of GnRH, FDA-approved for advanced prostate cancer. It suppresses testosterone to castrate levels, starving hormone-sensitive tumour growth rather than attacking it directly. No peptide sold as a research chemical or supplement has been shown to kill cancer in humans. That claim lives in preclinical laboratory research, not clinical evidence.

What are the negative effects of peptides?

It depends which category of peptide.

  • FDA-approved GLP-1 drugs list gastrointestinal effects as their most common adverse reactions: nausea, vomiting, diarrhoea and constipation, reported in the majority of trial participants. Their labels also disclose rarer but serious risks such as pancreatitis and gallbladder disease.
  • Unregulated research peptides carry a different kind of risk. FDA’s own review of proposed bulk peptide substances repeatedly flags immunogenicity risk from aggregation and peptide-related impurities. For many entries it states that it has no, or only limited, safety-related information.

The two categories are not interchangeable, and this page does not extrapolate one’s side-effect profile onto the other.

What is not known

  • No long-term cancer-incidence study exists for most research peptides. They are sold research-use-only, outside clinical trial infrastructure, so nobody is tracking cancer outcomes in the people using them.
  • Absence of a reported signal is not evidence of safety. A peptide with no published cancer finding may simply never have been studied for that outcome, in humans or in an animal cancer model.
  • Even the approved boxed warning is an unresolved question. FDA required the warning because of a rodent finding, not because human harm was demonstrated, and the label says so directly.
  • Mechanism is not outcome. VEGFR2 activation and IGF-1 elevation are documented, measurable effects. Neither paper measuring them set out to test cancer incidence, and neither found it.

US legal status - Research use only

BPC-157 and most GH-secretagogue peptides sold as 'research chemicals' have no FDA-reviewed safety package at all - no boxed warning, no contraindication list, no post-market surveillance. That is a smaller safety net than an approved drug carries, not a larger one.

AU legal status - Not on the ARTG

Not on the Australian Register of Therapeutic Goods, so the TGA has not assessed it for safety, quality or effectiveness. Goods that are not on the ARTG cannot lawfully be supplied or advertised in Australia except through a specific pathway - the Special Access Scheme, an Authorised Prescriber, a clinical trial, or personal importation.

Regulators reach their own conclusions on their own timelines. Where these two disagree, the difference is the point - not an error.

Common questions

Do GLP-1 drugs cause cancer?

Their labels carry a boxed warning for thyroid C-cell tumours because the drugs cause them in rodents at clinically relevant exposures. Every label states that whether this happens in humans is unknown, because the human relevance of the rodent finding has not been determined. The warning is real and mandated, but it settles nothing either way.

Can peptides like BPC-157 cause cancer by promoting blood vessel growth?

This is a theoretical concern, not a documented one. BPC-157 has been shown to activate VEGFR2 and promote angiogenesis in laboratory and animal work. Tumours also need new blood vessels to grow past a small size, so the mechanisms overlap in principle. Nobody has tested whether BPC-157 increases tumour growth or incidence in humans or in animal cancer models. It is an inference from mechanism, not a finding.

Do growth-hormone-releasing peptides raise cancer risk by raising IGF-1?

Growth hormone secretagogues measurably raise serum IGF-1, a growth factor with known roles in cell proliferation. That is documented. Whether the IGF-1 rise from these peptides changes a person's cancer risk has not been established in controlled human data. The question is biologically plausible and unanswered.

Should someone with a personal or family history of cancer avoid peptides?

That depends on the specific peptide and history, and it is a conversation for a prescriber or oncologist who knows the details. Approved GLP-1 products name specific contraindications (personal or family MTC, MEN 2). Most research peptides carry no labelled guidance at all, which is a gap, not a reassurance.

What are the top 3 peptides?

There is no evidence-based ranking across peptides, because they are not directly comparable products. Most peptides on informal top-peptide lists are research compounds without a controlled human trial. A small number are FDA-approved drugs evaluated for a specific indication. Semaglutide, tirzepatide and liraglutide are among the approved peptide drugs with controlled trial evidence, each approved for a defined use, not for peptides generally. See this site's semaglutide, tirzepatide and liraglutide pages for what each has shown. A peptide's popularity online shows what people are interested in, not what a trial has shown.

References (11 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

  1. 1.Sigalos JT, Pastuszak AW, Allison A et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017;11(6):1752-1757.StudyPMID 28830317full text
  2. 2.Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538.Randomised trialPMID 28617838full text
  3. 3.Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333.StudyPMID 27847966
  4. 4.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.ReviewPMID 30915550
  5. 5.Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2).ReviewPMID 40005999full text
  6. 6.WEGOVY (semaglutide) full prescribing information - boxed warning for thyroid C-cell tumours, human relevance stated as undetermined.- DailyMed, National Library of Medicinelabel
  7. 7.MOUNJARO (tirzepatide) full prescribing information - boxed warning for thyroid C-cell tumours in rats, human relevance stated as undetermined.- DailyMed, National Library of Medicinelabel
  8. 8.SAXENDA (liraglutide) full prescribing information - boxed warning for thyroid C-cell tumours in rats and mice, human relevance stated as undetermined.- DailyMed, National Library of Medicinelabel
  9. 9.FDA bulk drug substance safety-risk list - cathelicidin LL-37 entry citing nonclinical findings of protumorigenic effects in some tissues.- US Food and Drug Administrationregulatory
  10. 10.FDA bulk drug substance safety-risk list - repeated immunogenicity-from-impurities language and "no, or only limited, safety-related information" findings across multiple peptide entries.- US Food and Drug Administrationregulatory
  11. 11.LUPRON DEPOT (leuprolide acetate) full prescribing information - synthetic nonapeptide GnRH analogue indicated for advanced prostate cancer, works by suppressing testosterone to castrate levels.- DailyMed, National Library of Medicinelabel

Keep reading

Related guides